P.J. : Ensayo que se inició en Julio 2013 de la mano del Instituto Mario Negri de Italia con la colaboración de PharmaMar y autorizado por la Agencia Italiana del Medicamento . Los resultados del primer corte del ensayo se adelantaron en el pasado congreso ASCO y los resultados Maduros podrían estar listos este Octubre :
Estimated Study Completion Date : October 2016 .
**************************************************
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) (ATREUS).
Published March 19, 2016 | By admin
PharmaMar has actually announced data from a Phase 2 study in patients along with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.1) of patients treated along with the anticancer drug trabectedin in second line were alive and without development at 12 weeks. The median progression-free survival (PFS) in these 17 evaluated patients was 8.3 weeks. There were 5 patients that keep on receiving trabectedin beyond 12 weeks.
“Mesothelioma patients usually do not respond to second-line treatments so the preliminary data we observed below is encouraging. This study likewise adds to the scarce evidence-based science in this disease, as the usage of trabectedin is based on its direct effect on tumor-associated macrophages and its efficacy in various tumors, including soft tissue sarcomas.” Said Diego Luigi Cortinovis, MD, Medical Oncologist San Gerardo Hospital, Monza, Italy. “Provided the aggressiveness of this illness and the inadequate response of this mesothelioma population, the indication that this treatment may be energetic in these patients is a significant arrive and warrants further investigation in a bigger population.”
...